Invasive fungal infection (IFI) is a life-threating infectious disease in high-risk neonates. Strategies for the treatment and prevention of IFI in neonates in Japan remain unclear. We conducted a nationwide retrospective survey to determine IFI incidence between January 2014 and October 2015. Primary survey questionnaires were submitted to 309 medical facilities that regularly treat high-risk neonates. The questionnaire assessed IFI incidence during the study period, methods for preventing fungal infection in early delivery neonates, and methods for preventing mother-to-child fungal transmission. The secondary questionnaire was for facilities that had IFI cases and replied to the primary questionnaire. In total, 128 medical facilities (41.4%) completed the primary questionnaire, 17/128 facilities recorded 23 proven or probable IFI cases. Estimated annual IFI incidence was 0.33/1000 live births of hospitalized neonates. Patient data at IFI onset were available for all 23 patients. Birth weight was < 1000 g in 18 patients. Causative microorganisms were identified in 22 patients. Candida species (n = 21) were the most common pathogens, and one patient had mucormycosis. The mortality rate was 17.4%. Regarding neonatal fungal prophylaxis, 55/128 facilities (43.0%) reported administering therapy. The most frequently used prophylactic drugs were fluconazole, then micafungin. Fungal prophylaxis for mothers who showed fungal colonization was performed in 30/128 facilities (23.4%). Oxiconazole vaginal tablets were most commonly used as prophylaxis for high-risk mothers. In Japan, the diagnosis, treatment, and prevention of neonatal IFI varied. Continuous surveillance and treatment regimen for neonatal IFI are required to improve outcomes in high-risk neonates.
Introduction
Invasive fungal infection (IFI) is a life-threating infectious disease that occurs in immunocompromised patients. In pediatric medicine, most cases of immunodeficiency are congenital or secondary to diseases such as hematomalignancies and rheumatic disease with immunosuppressive therapy, and also in high-risk neonates. The burden of disease attributed to neonatal IFI varies by geographic region and maternal and neonatal risk factors. 1 Approximately, one million neonates are born every year in Japan. Japan has one of the lowest neonatal mortality rates in the world. 2 Contrastingly, the preterm birth rate is approximately 5% in Japan. 3 IFI is a notable cause of mortality and morbidity in very preterm or very low birth weight (VLBW) infants (birth weight < 1500 g).
Other risk factors for IFI include the use of central venous lines, intubation, parenteral nutrition, broad-spectrum antibiotics administration, prolonged hospitalization, abdominal surgery, exposure to an H 2 blocker, and colonization with Candida spp. 4 In a nationwide survey on pediatric IFI in Japan conducted between 2005 and 2009, only six cases of neonatal IFI were reported. 5 However, the main targets of this retrospective survey were medical facilities that had pediatric wards. Therefore, appropriate guidelines for the prevention and treatment of IFI in neonatal medicine in Japan were not developed. The purpose of this study was to assess the incidence of IFI in neonates through a nationwide survey of medical facilities with neonatal intensive care units (NICU) and to formulate effective guidelines for the prevention and treatment of neonatal IFI. This study is important for improving the prognosis of high-risk neonates.
Methods
We conducted a nationwide retrospective survey in November 2015, in order to determine the incidence of IFI between January 2014 and October 2015. This survey was performed with the regular annual nationwide survey of neonatal bacterial infectious diseases by the committee for infection and vaccine promotion of the Japan Society for Neonatal Health and Development. The chief medical officer of each medical facility filled the questionnaire based on information from the patients' charts. The primary survey questionnaire was sent to 309 medical facilities that regularly treat high-risk neonates. The primary questionnaire assessment canvassed the incidence of IFI during the study period, the method for preventing fungal infection in high-risk neonates soon after birth. High-risk neonates were defined as very preterm neonates (gestational age ≤28 weeks), those with very low birth weight (≤1000 g), and infants receiving broad-spectrum antibiotic therapy excluding the initial therapy with ampicillin and gentamicin. 6 The primary questionnaire also assessed the method of maternal antifungal prophylaxis for preventing mother with fungal colonization to high-risk neonate transmission. 
Results

Results from the primary questionnaire
The questionnaires were sent to 309 medical facilities in the Neonatal Research Network Japan and other related medical facilities that also had NICU or treated neonates. In total, 128 facilities replied to the primary questionnaire and the response rate was 41.4%. Notably, 24/128 facilities reported having managed 34 IFI cases including possible IFI, and 55/128 (43.0%) medical facilities offered neonatal fugal prophylaxis. The most frequently used prophylactic drug was fluconazole (n = 35), followed by micafungin (n = 16) ( (Table 3) . Eleven cases of IFI were reported in 2014 (January-December 2014), and 12 in 2015 (January-October 2015). The annual number of hospitalized patients in these 128 medical facilities was 37,457. The estimated annual incidence of IFI was 0.33 per 1000 live births of hospitalized neonates. Patient data on the onset of IFI was available for all 23 patients. The median gestational age at birth was 26 weeks (range: 22-33 weeks), the median birth weight was 891 g (range: 394-2,040 g), and 13 patients were male. The birth weight was < 1000 g in 18 patients and > 1500 g in four patients, two of whom had underlying diseases. The median age at onset of IFI was 18 days (range: 0-161 days). Early-onset infection occurred in 10 cases, and 20/23 cases presented with IFI within 30 days after birth. The rates of occurrence of the associated risk factors are presented in Table 4 . The most frequent laboratory finding of patients with IFI at initial diagnosis was a low platelet count. The clinical diagnoses of the gross number of fungal infection revealed that 15 cases were sepsis; six were pneumonia; five were dermatitis; three were septic shock; two were intestinal candida infection; and one exhibited meningitis/ventriculitis, peritonitis, liver abscess, and disseminated infection. The causative microorganisms were identified in 22 patients. Candida species (n = 21) were the most commonly isolated pathogen, and one patient was reported to have mucormycosis. In 13/21 patients, IFI due to candida was caused by C. albicans, five by C. parapsilosis, two by C. glabrata, and one by C. albicans and C. glabrata. The causative microorganism was not identified for the remaining one probable case of IFI. As a first-line antifungal treatment, 11 patients received micafungin, eight received fosfluconazole, three received fluconazole, one received liposomal amphotericin B. In nine cases, the first-line antifungal treatment had to be changed (Table 3) . Liposomal amphotericin B was finally prescribed for five patients.
The median duration of treatment in survivors was 34 days (range: 3-110 days). Four patients died during the antifungal therapy, all of whom had extremely low birth weights. The median postnatal age at death was 80 days (range: 11-225 days). Among the deceased patients, two were infected with C. parapsilosis and one each with C. albicans and Mucorales. Notably, 2/4 (50%) of those who died had been treated with micafungin, one with liposomal amphotericin B, and one with fluconazole. The median duration of treatment for those who died was 33 days (range: 4-64 days). Involvement of other organs apart from the primary site of infection was also noted in those who died. Two patients died within 1 week of the onset of IFI. IFI directly contributed to the death of these two patients. One patient who survived exhibited sequelae and was treated at home on oxygen therapy. Of 17 medical facilities that reported cases of IFI, 12 (70.6%) routinely provided antifungal prophylaxis to high-risk neonates. The incidence of IFI in the facilities that provided antifungal prophylaxis to neonates (2.3 per 1000 live births of hospitalized neonates) was lower than the incidence of IFI in those that did not provide antifungal prophylaxis to neonates (4.0 per 1000 live births of hospitalized neonates), but this difference was not statistically significant. Also, of the 17 medical facilities that reported cases of IFI, six (35.3%) routinely provided antifungal prophylaxis to high-risk mothers. The incidence of IFI in the facilities that provided antifungal prophylaxis to mothers (2.8 per 1000 live births of hospitalized neonates) was higher than the incidence of IFI in those that did not provide antifungal prophylaxis to mothers (2.6 per 1000 live births of hospitalized neonates), but this difference was not statistically significant. Again, of 17 medical facilities that reported cases of IFI, 14 (82.4%) routinely provided antifungal prophylaxis to high-risk neonates and/or high-risk mothers. The incidence of IFI in the facilities that provided antifungal prophylaxis (2.6 per 1000 live births of hospitalized neonates) was lower than the incidence of IFI in those that did not provide antifungal prophylaxis (3.7 per 1000 live births of hospitalized neonates), but this difference was not statistically significant. Thus, the provision of antifungal prophylaxis did not statistically make a difference regarding the incidence of IFI in our study.
Discussion
To the best of our knowledge, this is the first report on the nationwide surveillance of neonatal IFI in Japan. This study clarified the incidence of neonatal IFI and the actual state of prophylaxis against IFI for mothers and babies in Japan. The estimated annual IFI incidence in the present study was 0.33 per 1000 live births of hospitalized neonates. According to the reports from other countries, Xia et al. reported that the incidence of invasive candidiasis was 0.74 cases per 1000 preterm discharges from NICU in China. 8 Nguyen et al. also reported the incidence of invasive candida infection was one case per 1000 patients below 32 weeks gestational age per year in France. 9 Oeser et al. The incidence of our study was similar to the above studies. Notably, several studies showed higher incidence rate (7%) than our study. 11, 12 Possible explanations for these discrepancies include differences in patient demographics, medical practices, and surveillance systems.
Regarding the methods for the prevention neonatal IFI, the systematic review of randomized control trials on the use of antifungal chemotherapy to prevent neonatal IFI in VLBW infants reported that prophylactic fluconazole and oral nystatin were both highly effective. Both agents were safe without significant toxicities. 13 In our study, only 43% of medical facilities prescribed antifungal prophylaxis for high-risk neonates; 16/55 facilities (29.1%) chose micafungin as the prophylactic agent. Therefore, the antifungal prophylaxis for high-risk neonates was not widely performed, and the prophylactic agents administered were varied in Japan. Pregnancy increases the frequency of vaginal Candida colonization. 14 Concerning maternal antifungal prophylaxis, there were two eligible randomized controlled trials in which pregnant women were treated for vulvovaginal candidiasis and where preterm birth was reported as an outcome. There was a significant in the number of spontaneous preterm births in treated compared with untreated women. 15, 16 In our study, fungal prophylaxis for mothers who showed fungal colonization was administered in 23.4% of the medical facilities. Antifungal vaginal tablets were the most common prophylactic agents prescribed. Further studies are required to clarify the efficacy of antifungal prophylaxis for mothers in Japan.
In our study, 23 cases of IFI were reported. The most common pathogenic fungus was Candida spp, of which C. albicans was the predominant species. Notably, nonalbicans Candida spp. were also isolated in our study. Although C. albicans has historically been the most prominent species involved in IFI, C. parapsilosis is increasing in frequency, and neonates are disproportionately affected. In a Tunisian study, C. albicans was the predominant species up to 2006, and a shift in the species spectrum was observed with an increase in non-albicans species, predominantly C. parapsilosis. 17 Another study revealed that C. parapsilosis was the leading causative pathogen of IFI and was isolated in 33.3% of the patients. 18 Regarding the treatment of C. parapsilosis infection, echinocandin-resistant strains, which may be associated with acquired mutations of the gene encoding (1→3)-β-D-glucan (BDG) synthase have been involved. 19 Practically, 60% of cases of IFI caused by C. parapsilosis required a change of the initial fungal treatment in our study. In our study, one patient with mucormycosis was reported, who developed a disseminated infection and died. The pathogenic diagnosis was made by autopsy. IFI caused by Mucorales is rare in children, and data on mucormycosis in neonates are lacking. Mucormycosis is a life-threatening infection in neonates, and amphotericin B is the recommended antifungal agent. 20 IFI is associated with high morbidity and mortality in preterm neonates. The main risk factors of IFI are multiple antibiotics including third-generation cephalosporins, central venous catheters, parenteral nutrition, immunosuppression, and VLBW. 21, 22 Colonization with Candida spp. in neonates is also an important risk factor of IFI. Neonates acquire Candida spp. either via maternal-vertical transmission or nosocomial acquisition in the nursery. Multiple sites may become colonized, and a direct correlation between fungal colonization and subsequent progression to invasive candidemia was determined. 4 Vaginal delivery, low birth weight, and low gestational age may also be considered risk factors for candida colonization. 23 We studied the frequency of the established risk factors for IFIs in the literature. 4 In our study, majority of the neonates with IFI had central venous catheterization (22/23), birth weight < 1000 g (18/23), gestation age ≤28 weeks (17/23), and no antifungal agent prophylaxis (16/23) . Contrastingly, an underlying disease without ELBW (11/23), systematic corticosteroid therapy for neonates (11/23) and vaginal Candida colonization of the mother (10/23) were noted in < 50% of the IFI cases in our study. Invasive candidiasis is uncommon in infants with a birth weight > 1500 g. Infants at greatest risk are those exposed to broad-spectrum antibiotics and with platelet counts of < 50,000/mm. 3, 24 In our study, birth weight was > 1,500 g in four patients, two of whom had underlying diseases. The definitive diagnosis of IFI relies on the growth of fungi in blood culture from otherwise sterile sites, but our study identified 70% of the cases via this method. Goudjil et al. reported that the changes in the serum BDG levels might be of value in evaluating the efficacy of antifungal therapy. 25 Zhao et al. also reported the usefulness of BDG for identifying the diagnostic and prognostic markers of IFI in preterm infants. The sensitivity in diagnosing IFI by a BDG cutoff > 10 pg/ml was 68.3% and specificity was 75.6%. 26 In our study, 6/23 cases were serologically diagnosed with IFI (a BDG value of > 11 pg/ml was considered as positive). Trovato et al. recently reported the usefulness of fungal DNA detection in blood culture for the diagnosis of invasive candidiasis in neonates. 27 In our study, one patient was diagnosed with IFI based on the detection of fungal DNA. Regarding the treatment, according to the European Society of Clinical Microbiology and Infectious Diseases guidelines for the diagnosis and management of Candida disease in neonates and children, amphotericin B deoxy cholate, liposomal amphotericin B, amphotericin B lipid complex, fluconazole, micafungin, and caspofungin can all potentially be used for the treatment of invasive candidiasis in neonates. 28 Over the past decade, the number of antifungal agents in development has increased, but the majority are not labeled for use in neonates. 29 In our study, micafungin was most commonly used as the initial antifungal treatment, followed by fosfluconazole. However, the treatment of eight cases was changed from the initial treatment during the clinical course. The duration of treatment in survivors was variable (range: 3-110 days). It is important that a treatment regimen for neonatal IFI is established. The mortality rate in our study was 17.4% (4/23), which is similar to a study from China (19.3%) but lower than a report from England (31%). 8, 10 All deceased patients were ELBW infants. The causative fungi of the deceased cases were Candida spp. (n = 3) and mucormycosis (n = 1). A report on the virulent factors of Candida spp. described that individual isolates of Candida spp. were varied in their virulent properties such as adhesion and cytotoxicity. However, highly virulent Candida strains are associated with clinical outcomes. 30 It is also important that the isolated strain from IFI was stocked and its virulence analyzed precisely. There are several limitations to our study. The first was the low response rate to the primary questionnaire (41.4%), which could have led to an underestimation of the incidence of IFI. However, the responding medical facilities included 33 qualified main training hospitals with NICU (units for level III intensive care), which are evenly distributed throughout Japan. The annual numbers of VLBW infants delivered in Japan and in these medical facilities were 7500 and 4000, respectively. 31 The annual number of VLBW infants in this survey was calculated based on the data from the medical facilities. We think that the present results are representative of the current Japanese situation because approximately half of VLBW infants were covered in this survey. Second, our study identified only 23 cases of proven or probable IFI. Improved diagnostics for fungi are required to guide the initiation of prompt antifungal therapy in premature infants. 32 Finally, we did not collect any data on the antifungal susceptibility of the isolated fungi, and the dosage of antifungal agent used. To clarify the efficacy of the antifungal treatment, these data are important. 33 Further surveillance studies are required to investigate these points.
In conclusion, our nationwide survey identified 23 IFI cases during the 22-month study period. The majority of IFI cases were caused by Candida infection, and the mortality rate was 17.4%. According to a large cohort study in the United States, the incidence of invasive candidiasis in the NICU decreased over the 14-year study period. Increased use of fluconazole prophylaxis, empirical antifungal therapy, and decreased use of broad-spectrum antibiotics may have contributed to this observation. 34 In Japan, the diagnosis, treatment, and prevention of neonatal IFI varied. Continuous surveillance and the establishment of a treatment regimen against neonatal IFI, including regulation of the use of broad-spectrum antibiotics, are required to improve outcomes in high-risk neonates.
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